Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 10:28AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.44 Insider Own10.02% Shs Outstand143.83M Perf Week1.52%
Market Cap814.50M Forward P/E12.03 EPS next Y0.47 Insider Trans-2.36% Shs Float128.69M Perf Month5.07%
Income-62.56M PEG- EPS next Q0.01 Inst Own36.62% Short Float8.02% Perf Quarter18.40%
Sales191.41M P/S4.26 EPS this Y112.96% Inst Trans9.06% Short Ratio8.16 Perf Half Y-27.73%
Book/sh2.50 P/B2.28 EPS next Y576.19% ROA-12.92% Short Interest10.32M Perf Year-49.74%
Cash/sh2.24 P/C2.55 EPS next 5Y- ROE-16.69% 52W Range4.71 - 12.43 Perf YTD-36.65%
Dividend Est.- P/FCF- EPS past 5Y6.35% ROI-14.44% 52W High-54.18% Beta1.45
Dividend TTM- Quick Ratio5.05 Sales past 5Y3168.98% Gross Margin88.59% 52W Low20.91% ATR (14)0.22
Dividend Ex-Date- Current Ratio5.60 EPS Y/Y TTM35.94% Oper. Margin-33.81% RSI (14)53.44 Volatility4.24% 3.61%
Employees300 Debt/Eq0.25 Sales Y/Y TTM30.37% Profit Margin-32.69% Recom1.43 Target Price10.14
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q59.39% Payout- Rel Volume1.23 Prev Close5.57
Sales Surprise6.86% EPS Surprise48.79% Sales Q/Q46.19% EarningsAug 01 BMO Avg Volume1.26M Price5.70
SMA201.64% SMA504.18% SMA200-14.84% Trades Volume296,592 Change2.24%
Date Action Analyst Rating Change Price Target Change
Nov-04-22Downgrade Oppenheimer Outperform → Perform
May-05-22Resumed Cantor Fitzgerald Overweight $34 → $25
Dec-10-21Upgrade Oppenheimer Perform → Outperform $33 → $31
Oct-28-21Downgrade Oppenheimer Outperform → Perform $32
Jan-25-21Reiterated H.C. Wainwright Buy $30 → $35
Nov-03-20Reiterated H.C. Wainwright Buy $34 → $28
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
Today 06:00AM
Jul-12-24 04:39AM
Jul-11-24 03:27PM
Jul-02-24 06:00AM
Jun-17-24 04:46AM
12:16PM Loading…
Jun-14-24 12:16PM
Jun-05-24 06:00AM
Jun-04-24 05:30PM
Jun-03-24 06:30PM
May-30-24 06:00AM
May-14-24 06:00AM
May-09-24 06:00AM
May-07-24 09:55AM
May-03-24 01:02PM
10:56AM Loading…
May-02-24 10:56AM
May-01-24 06:00AM
Apr-30-24 06:00AM
Apr-16-24 10:48AM
Apr-15-24 06:00AM
Apr-09-24 06:00AM
Mar-17-24 05:20PM
Feb-29-24 08:30AM
Feb-27-24 08:30AM
Feb-16-24 09:22AM
Feb-15-24 07:25AM
06:32AM Loading…
Feb-08-24 10:00AM
Feb-05-24 08:30AM
Jan-18-24 04:30PM
Jan-05-24 06:00AM
Dec-28-23 09:40AM
Dec-20-23 06:00AM
Dec-10-23 06:59AM
Nov-23-23 09:55AM
Nov-20-23 09:40AM
Nov-13-23 06:00AM
Nov-07-23 10:30AM
Nov-03-23 09:40AM
Nov-02-23 06:00PM
Oct-26-23 03:00PM
Oct-19-23 10:31AM
Oct-16-23 09:29AM
Oct-14-23 01:15PM
Oct-13-23 12:00PM
Oct-12-23 12:13PM
Oct-11-23 10:15AM
Oct-09-23 11:10AM
Oct-06-23 09:24AM
Oct-04-23 08:17AM
Oct-03-23 07:43AM
Sep-29-23 09:40AM
Sep-27-23 09:34AM
Sep-26-23 10:56AM
Sep-21-23 06:00AM
Sep-18-23 08:52AM
Sep-06-23 09:55AM
Aug-25-23 09:40AM
Aug-21-23 06:00AM
Aug-03-23 07:15AM
Jul-27-23 07:41AM
Jul-20-23 06:00AM
Jul-19-23 12:05PM
Jul-18-23 10:55AM
Jul-11-23 10:55AM
Jul-03-23 10:42AM
Jul-02-23 05:59PM
Jun-30-23 04:02PM
Jun-29-23 04:05PM
Jun-20-23 09:00AM
Jun-06-23 08:11AM
Jun-01-23 09:00AM
May-26-23 05:16PM
May-23-23 06:56AM
May-17-23 12:14PM
May-11-23 12:00PM
May-09-23 06:02AM
May-04-23 07:15AM
May-03-23 07:51AM
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MacKay-Dunn R. HectorDirectorMay 21 '24Sale5.745,63032,31618,595May 22 04:07 PM
Leversage JillDirectorMay 21 '24Sale5.745,61032,20112,918May 22 04:09 PM
Billen DanielDirectorMay 21 '24Sale5.745,25230,14628,141May 22 04:14 PM
Jayne David R.W.DirectorMay 21 '24Sale5.744,94628,39044,364May 22 04:11 PM
Balakrishnan BrindaDirectorMay 21 '24Sale5.745202,98517,523May 22 04:16 PM
Greenleaf PeterChief Executive OfficerMar 06 '24Sale5.60126,981711,0941,522,114Mar 07 04:46 PM
Robertson Stephen P.EVP, General CounselMar 06 '24Sale5.6057,745323,372443,824Mar 07 04:41 PM
Donley Matthew MaxwellEVP, Ops & StrategyMar 06 '24Sale5.5140,665224,064584,072Mar 07 04:43 PM
Miller Joseph MChief Financial OfficerMar 06 '24Sale5.6034,811194,942495,928Mar 07 04:44 PM
Habig Scott MichaelChief Commercial OfficerMar 06 '24Sale5.6017,77799,551474,587Mar 07 04:42 PM
Knappertz VolkerEVP, Research and DevelopmentFeb 27 '24Sale6.104,93030,073319,128Feb 29 04:11 PM
Knappertz VolkerEVP, Research and DevelopmentFeb 20 '24Sale5.4825,146137,800324,058Feb 22 04:35 PM
Habig Scott MichaelChief Commercial OfficerFeb 20 '24Sale5.4815,86786,951492,364Feb 22 04:33 PM